Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

InMed Pharmaceuticals  / Equity Bottom-Up

<div>
<div>
<div>
<div>
<ul>
<li>BayMedica’s exponential growth momentum continues.</li>
<li>This morning, InMed Pharmaceuticals (INM) provided a business update on the progress of its BayMedica subsidiary, a leading supplier of rare non- psychoactive cannabinoids to the health &amp; wellness sector.</li>
<li>In an early disclosure, ahead of a formal release of InMed’s 4QFY23 earnings, expected in September, the company signaled that BayMedica will report a 123% Q/Q increase in revenues to more than $2.3M for the fiscal fourth quarter ended June 30, 2023. </li>
</ul>
</div>
</div>
</div>
</div>






BayMedica’s exponential growth momentum continues.
This morning, InMed Pharmaceuticals (INM) provided a business update on the progress of its BayMedica subsidiary, a leading supplier of rare non- psychoactive cannabinoids to the health &amp; wellness sector.
In an early disclosure, ahead of a formal release of InMed’s 4QFY23 earnings, expected in September, the company signaled that BayMedica will report a 123% Q/Q increase in revenues to more than $2.3M for the fiscal fourth quarter ended June 30, 2023. 






InMed Pharmaceuticals, Inc. - Another Super BayMedica Quarter Signaled